EP Patent

EP2314291A1 — Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis

Assigned to Sanofi SA · Expires 2011-04-27 · 15y expired

What this patent protects

This invention is related to the use of the combination of teriflunomide or a pharmaceutically acceptable salt thereof and glatiramer acetate for treating multiple sclerosis.

USPTO Abstract

This invention is related to the use of the combination of teriflunomide or a pharmaceutically acceptable salt thereof and glatiramer acetate for treating multiple sclerosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP2314291A1
Jurisdiction
EP
Classification
—
Expires
2011-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.